Industry Spotlights & Insight Articles

Most Anticipated Presentations: Vaccines Europe

Discover key event highlights from Oxford Global's upcoming Vaccines Congress 2022.

In anticipation of our Vaccines Europe: In-Person event happening on 29-30 November 2022 in Berlin, Germany, we look at 3 of the most anticipated Industry presentations. Vaccines Europe is an intensive 2-day in-person conference that delves into the latest in vaccine research, platform technologies, analytics, and vaccine development.

A meeting place for experts working within cutting-edge vaccine research and development, presentations will delve into the different applications of vaccines in therapeutics.

From antibodies against infectious diseases and T cell vaccines to adapting vaccines against new variants and developing vaccines for antimicrobial resistance pathogens, Vaccines Europe will provide a unique opportunity to gain a comprehensive understanding of the current and future vaccines landscape.

With a high-quality program devised with the help of our esteemed advisory board, not-to-miss industry presentations include:

1.) ‘Plasmid: A Vaccine Platform 30 Years In The Making’

  • Review of plasmid’s role in vaccines and other therapies (DNA vaccine, mRNA vaccine, gene therapy)
  • Potential for plasmid as a platform
  • Development of a scalable plasmid process to meet various needs

Matthew Watson, Principal Scientist, Merck & Co

2.) ‘New Developments In Plant-Made Vaccines’

  • Production platforms for vaccines
  • Plant-based protein expression for recombinant subunit vaccines
  • Versatility: Individualized cancer vaccines (the MagnIcon (TM) experience)
  • Speed: the bbola trivalent vaccine Zmap
  • Scalability: Medicago’s COVID-19 vaccine
  • New developments (ICON Genetics / Denka norovirus vaccine)
  • Real and perceived hurdles / conclusions

John-Edward Butler-Ransohoff, Vice President, Open Innovation Public-Private Partnerships, Bayer AG

3.) ‘Adjuvanted Vaccines For Pandemic Response’

  • Characteristics of an adjuvant for pandemic response vaccines
  • Applications in influenza vaccines
  • Application in SARS-CoV2 vaccines

Margherita Coccia, Technical Project Leader, New Adjuvants Discovery, GlaxoSmithKline

Over 300 senior attendees from leading pharmaceutical, biopharmaceutical, academics, CRO and solution provider companies will be attending Vaccines Europe: In-Person.

Sign up for the brochure HERE and register HERE today.

For more information on Oxford Global’s Biologics 2022 event series, visit: https://oxfordglobal.com/biologics/upcoming/